Axim Biotechnologies Inc (AXIM)

[Devolution]

With 330 million people in the US, and 7.75 billion worldwide (over 20x the population of the US), Versea' is most definitely focusing on the global market.

Its been just over 1 month since the contract was signed, and just under 1 month since the 1st conference that launched Axim's products, with another equally important conference less than a week away.

Can you imagine the electricity buzzing around both of these companies (Axim & Versea')?

As a global company, Versea' is literally working 24 hours a day, promoting Axim's products and seeking approvals overseas while the rest of us are sleeping over here.

I'm guessing the next groundbreaking announcements will be in the overseas markets, such as approvals by the EU and Canada. The markets in China, South America, and the Middle East, etc., certainly can't be ignored either, as DED is a problem that effects people on all continents.

Certainly no one is sitting around on their hands or twiddling their thumbs at either of these companies at this most critical time of development and expansion.

I don't doubt that those at Axim who think outside the box are also discussing further product possibilities.

2023 should prove to be a major breakout year for this small biotechnology start up.